50709-35-8,
2,5-Dichlorophenylhydrazine hydrochloride,
(2,5-dichlorophenyl)hydrazine hydrochloride,
(2,5-Dichlorophenyl)hydrazine monohydrochloride,
2,5-Dichlorophenylhydrazinehydrochloride,
Hydrazine, (2,5-dichlorophenyl)-, monohydrochloride,
AK-88779,
2,5-dichlorophenylhydrazine, chloride,
EINECS 256-729-1,
PubChem7525,
AC-4402,
AC1MJ3JT,
ACMC-1ATO7,
KSC491E8F,
SCHEMBL967050,
CTK3J1282,
DTXSID90198763,
2,5-Dichlorophenylhydrazine, HCl,
RQZTURFFWSJCMT-UHFFFAOYSA-N,
ACN-S003744,
ACT11122,
KS-00000VU1,
ZX-AT029570,
ANW-44848,
CD-426,
MFCD00052266,
AKOS001476036,
GS-3049,
MCULE-2595143184,
RTC-020824,
TRA0015168,
VZ22733,
ACM50709358,
AN-12014,
CC-07730,
SY004794,
AB0006653,
AB1000223,
AX8003466,
DB-020054,
ST2402144,
TC-020824,
FT-0639934,
ST50827003,
1-(2,5-dichlorophenyl)hydrazine hydrochloride,
EN300-96340,
2,5-Dichlorophenylhydrazine hydrochloride, 98%,
Z-3860,
MFCD00052266 (97+%),
C-11276,
I01-1549,
null,
D03TDE,
C6H7Cl3N2,
C6-H6-Cl2-N2.Cl-H,
6-Nitro-1H-indazole-3-carboxaldehyde,
CID3084937,
A7520,
2,5-Dichlorophenylhydrazine hydrochloride, 98% - 1G 1g,
GABAA receptor inverse agonist (Alzheimer's disease), Dainippon Sumitomo Pharma,
315203-37-3,